"Science fiction has become science," said an anti-aging biotech's CEO about the company's completing its $100 million Series B round of financing last week. "I think the world is going to be shocked."
"Science fiction has become science," said an anti-aging biotech's CEO about the company's completing its $100 million Series B round of financing last week. "I think the world is going to be shocked."